Jun Liu
MBBS, MSc, PhD
Novo Nordisk Research Fellow
Starting September 2021, Jun worked as a Novo Nordisk Research Fellow alongside Professor Cornelia van Duijn (Oxford Population Health) and Dr Joanna Howson (Novo Nordisk Research Centre Oxford).
The project, "An Integrative Cross-omics Study of Non-Alcoholic Fatty Liver Disease and Non-alcoholic Steatohepatitis," has led her to explore omics profiles and identify potential drug targets for NAFLD using proteomics, alongside integrating additional omics data.
Jun completed her clinical medicine degree at Shanghai Jiao Tong University in China in 2013 and gained experience in the clinical epidemiology of type 2 diabetes through a one-year research placement at Rui-Jin Hospital's Department of Endocrine and Metabolic Diseases in Shanghai.
She then advanced with an MSc in genetic epidemiology from the Erasmus Medical Center in Rotterdam, Netherlands. Jun's academic journey continued, culminating in a PhD on "Integration of Multi-Omics in Type 2 Diabetes and Related Disorders Research."
In 2019, Jun relocated to Oxford to join Oxford Population Health as a postdoctoral researcher, focusing on multi-omics data integration for cardiometabolic and neurological disorders. In 2023, she achieved full registration with the General Medical Council (GMC) in the UK.
Key publications
-
Integration of epidemiologic, pharmacologic, genetic and gut microbiome data in a drug-metabolite atlas.
Journal article
Liu J. et al, (2020), Nat Med, 26, 110 - 117
-
An integrative cross-omics analysis of DNA methylation sites of glucose and insulin homeostasis.
Journal article
Liu J. et al, (2019), Nat Commun, 10
-
A Mendelian Randomization Study of Metabolite Profiles, Fasting Glucose, and Type 2 Diabetes.
Journal article
Liu J. et al, (2017), Diabetes, 66, 2915 - 2926
Recent publications
-
Dissecting metabolic dysfunction- and alcohol-associated liver disease (MetALD) using proteomic and metabolomic profiles.
Journal article
Liu J. et al, (2025), J Hepatol
-
Novel genetic insights into the roles of amino acids in metabolic dysfunction-associated steatotic liver disease
Preprint
Liu J. et al, (2024)
-
Genome-wide characterization of circulating metabolic biomarkers.
Journal article
Karjalainen MK. et al, (2024), Nature, 628, 130 - 138
-
Profiling the genome and proteome of metabolic dysfunction-associated steatotic liver disease identifies potential therapeutic targets.
Journal article
Liu J. et al, (2023), medRxiv
-
A Type 1 Diabetes Polygenic Score Is Not Associated With Prevalent Type 2 Diabetes in Large Population Studies.
Journal article
Srinivasan S. et al, (2023), J Endocr Soc, 7